1.
|
Kubota T: The role of S-1 in the treatment
of gastric cancer. Br J Cancer. 98:1301–1304. 2008. View Article : Google Scholar : PubMed/NCBI
|
2.
|
Shirasaka T, Nakano K, Takechi T, et al:
Antitumor activity of 1 M tegafur-0.4 M
5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against
human colon carcinoma ortho-topically implanted into nude rats.
Cancer Res. 56:2602–2606. 1996.PubMed/NCBI
|
3.
|
Blum M, Suzuki A and Ajani JA: A
comprehensive review of S-1 in the treatment of advanced gastric
adenocarcinoma. Future Oncol. 6:715–726. 2011. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Shimoyama S, Kiyokawa T, Nishida M and
Seto Y: S-1 monotherapy achieved twenty-month survival for
peritoneal lavage cytology-positive gastric cancer patient
undergoing noncurative resection. Gan To Kagaku Ryoho. 9:1411–1414.
2012.(In Japanese).
|
5.
|
Yamashita T, Arai K, Terashima T, et al: A
case report of S-1 monotherapy for advanced hepatocellular
carcinoma. Gan To Kagaku Ryoho. 9:1435–1437. 2012.(In
Japanese).
|
6.
|
Iwasa S, Yamada Y, Kato K, Goto A, Honma
Y, Hamaguchi T and Shimada Y: Long-term results of a phase II study
of S-1 plus irinotecan in metastatic colorectal cancer. Anticancer
Res. 9:4157–4161. 2012.PubMed/NCBI
|
7.
|
Kogashiwa Y, Nagafuji H and Kohno N:
Feasibility of concurrent chemoradiotherapy with S-1 administered
on alternate days for elderly patients with head and neck cancer.
Anticancer Res. 32:4035–4040. 2012.PubMed/NCBI
|
8.
|
Shirasaka T, Shimamato Y, Ohshimo H, et
al: Development of a novel form of an oral 5-fluorouracil
derivative (S-1) directed to the potentiation of the tumor
selective cytotoxicity of 5-fluorouracil by two biochemical
modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Shirasaka T, Shimamoto Y and Fukushima M:
Inhibition by oxonic acid of gastrointestinal toxicity of
5-fluorouracil without loss of its antitumor activity in rats.
Cancer Res. 53:4004–4009. 1993.PubMed/NCBI
|
10.
|
American Association for Cancer Research:
86th Annual Meeting: Proceedings; 36. American Association for
Cancer Research; Toronto: pp. 4061995
|
11.
|
Kitamura R, Satoh T, Maeda M and Tsuji A:
Enzyme immunoassay of potassium oxonate using specific antibody
isolated by immunosorbent gel. Yakugaku Zasshi. 114:171–175.
1994.(In Japanese).
|
12.
|
Matsushima E and Yoshida K, Kitamura R and
Yoshida K: Determination of S-1 (combined drug of tegafur,
5-chloro-2,4-dihydroxypyridine and potassium oxonate) and
5-fluorouracil in human plasma and urine using high-performance
liquid chromatography and gas chromatography-negative ion chemical
ionization mass spectrometry. J Chromatogr B Biomed Sci Appl.
691:95–104. 1997.
|
13.
|
Schwaninger AE, Meyer MR, Huestis MA and
Maurer HH: Development and validation of LC-HRMS and GC-NICI-MS
methods for stereoselective determination of MDMA and its phase I
and II metabolites in human urine. J Mass Spectrom. 46:603–614.
2011. View
Article : Google Scholar : PubMed/NCBI
|
14.
|
Liu K, Zhong D, Zou H and Chen X:
Determination of tegafur, 5-fluorouracil, gimeracil and oxonic acid
in human plasma using liquid chromatography-tandem mass
spectrometry. J Pharm Biomed Anal. 52:550–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Star-Weinstock M, Williamson BL, Dey S,
Pillai S and Purkayastha S: LC-ESI-MS/MS Analysis of Testosterone
at Sub-Picogram Levels Using a Novel Derivatization Reagent. Anal
Chem. 84:9310–9317. 2012.PubMed/NCBI
|
16.
|
Giorgianni F, Mileo V, Desiderio DM,
Catinella S and Beranova-Giorgianni S: Characterization of the
phosphoproteome in human bronchoalveolar lavage fluid. Int J
Proteomics. 2012:4602612012. View Article : Google Scholar : PubMed/NCBI
|
17.
|
de Mateo S, Estanyol JM and Oliva R:
Methods for the analysis of the sperm proteome. Methods Mol Biol.
927:411–422. 2013.
|
18.
|
Hirata K, Horikoshi N, Aiba K, et al:
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor
drug. Clin Cancer Res. 5:2000–2005. 1999.PubMed/NCBI
|
19.
|
Peters GJ, Noordhuis P, Van Kuilenburg AB,
et al: Pharmacokinetics of S-1, an oral formulation of ftorafur,
oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio
1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol.
52:1–12. 2003. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Mende B, Krauss J, Thyssen D, et al:
Pharmacokinetic study of S-1. Int J Clin Pharmacol Ther. 47:65–67.
2009. View
Article : Google Scholar
|